Protective Effect Of Valsartan Versus Benazepril On Left Ventricular Hypertrophy In Patients With Essential Hypertension A Systematic Review

Objective :To systematically evaluate the efficacy of valsartan versus benazepril in treating left ventricular hypertrophy in patients with essential hypertension.Methods: The databases of Ovid,Pubmed,MEDLINE,Embase,Cochrane Library,VIP,Chinese Biomedical Literature Database(CBM),Wan fang and CNKI were retrieved on line from the database foundation to April 2016.According to the method of Cochrane systematic review,the reviewers selected the Chinese and English literatures,which were randomized controlled trials(RCTs),about valsartan and benazepril in treating essential hypertension with LVH,extracted the data and assessed the quality of the screened literatures,and then conducted Meta-analysis with Rev Man5.2 software.Results: A total of 12 RCTs were finally included.Meta analysis showed that :(1)There was no statistical difference in lowing systolic blood pressure(SBP)(MD=?0.86,95% CI =?2.83~1.10,P=0.39)and diastolic blood pressure(DBP)(MD=0.48,95% CI =?0.63~1.59,P=0.40)between the valsartan group and benazepril group.(2)Valsartan group was better than benazepril group in reversing LVH [LVMI(MD=2.15,95% CI =0.62~3.70,P=0.006)?LVPWT(MD=0.14,95% CI =0.12~0.16,P<0.00001)].(3)Valsartan group had less adverse reaction than benazepril group(OR=0.32,95% CI =0.20~0.51,P<0.00001).Conclusions: The systematic review shows that valsartan is superior to the benazepril in the treatment of essential hypertension with LVH and its adverse reaction is less than that of benazepril.